Higher anti-A. simplex IgM levels in IBD patients receiving anti-TNF-α therapy may reflect an altered or enhanced early humoral immune response to A. simplex antigens likely due to the immunomodulatory effects of anti-TNF-α treatment on B-cell function and mucosal immunity. The gene discussed is TNF; the disease is inflammatory bowel disease.